Considerations for Potential Future Therapeutic Use of Psychedelic Drugs FDA Public Hearing

On Postpartum-depression, for the record

To the FDA,

Postpartum depression strikes one in seven mothers, it is a leading cause of maternal death by suicide, and it is fundamentally a disorder of a collapsing hormonal environment. This is the one depression we already know is hormone-driven. Ketamine and esketamine cut the risk of postpartum depression roughly in half in over twenty randomized trials, and ketamine’s active metabolites bind the very estrogen receptors that are crashing in these women. Yet not one of those trials measured a mother’s hormone levels, whether she was breastfeeding, or how those factors shaped her response and her infant’s safety. If the FDA wants a proving ground for taking sex and hormonal status seriously in psychedelic and rapid-acting antidepressant development, postpartum depression is it—because here the biology cannot be ignored, and the stakes include two lives.

Keep reading the full FDA submission on SUBSTACK

GALILEA FDA psychedelics hearing post partum depression ketamine psychedelic therapy Stephanie Karzon Abrams

@brookebschultz

Previous
Previous

TO BE WELL IS TO BE WILD

Next
Next

Dear healthcare Community: Women’s Health and Psychedelic Medicine Can’t Wait